ArticleFrontiers in oncology2022
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations.Cancer communications (London, England) · 2023Trial
- Safety evaluation of afatinib in patients with a history of interstitial lung disease using data from an administrative claims database in Japan.International journal of clinical pharmacy · 2026Article
- Design and development of novel EGFR inhibitors spanning all subgroups of EGFR mutations in non-small cell lung cancer.Innovation (Cambridge (Mass.)) · 2026Article
- A real-world study on the comparative effectiveness of first-line treatment regimens in advanced NSCLC patients withTherapeutic advances in medical oncology · 2026Article
- Histological-pathological and clinical T stage of primary adenoid cystic carcinoma of the lacrimal gland in a Chinese population.BMC cancer · 2025Article
- Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions.International journal of molecular sciences · 2025Review
- Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.Genes, chromosomes & cancer · 2025Article
- Challenges associated with the treatment of E709K and L858R double mutation in lung adenocarcinoma: A case report and literature review.Oncology letters · 2025Article
- Precision-medicine management recommendations for advanced non-small cell lung cancer: expert consensus.Future oncology (London, England) · 2025Article
- J-REGISTER: real-world study of Japanese patients withFuture oncology (London, England) · 2025Observational
- Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib.Thoracic cancer · 2025Article
- Unraveling Survival Determinants in Patients with Advanced Non-Small-Cell Lung Cancer withCurrent oncology (Toronto, Ont.) · 2025Article
- Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer.Japanese journal of clinical oncology · 2025Observational
- How to select between osimertinib or afatinib in P-loop and αC-helix compressing (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us in the early 2020s.Translational cancer research · 2025Article
- Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation.Frontiers in oncology · 2025Article
- Occurrence of respiratory and urinary tract infections in patients treated with docetaxel compared with afatinib based on a health insurance claims database in Japan.International journal of clinical pharmacy · 2024Article
- [Advances in Diagnosis and Targeted Therapy of G719X/L861Q/S768I Mutant Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Observational
- Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations inTranslational lung cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Previously, we developed a database of 693 patients with NSCLC and uncommon Methods: Patients were identified from a prospective database developed by Boehringer Ingelheim and Results: Of 1023 patients included, 587 patients were EGFR TKI-naïve and 425 were EGFR TKI-pretreated. The distribution of mutation categories was: major uncommon (41.4%); exon 20 insertions (22.3%); T790M (20.3%); and 'others' (15.9%); 38.6% had compound mutations. Overall, median TTF (TKI naïve/pretreated) was 10.7 and 4.5 months. ORR was 49.8% and 26.8%, respectively. In TKI-naïve patients, afatinib demonstrated activity against major uncommon mutations (median TTF: 12.6 months; ORR: 59.0%), 'other' mutations (median TTF: 10.7 months; ORR: 63.9%) including strong activity against E709X (11.4 months; 84.6%) and L747X (14.7 months; 80.0%), and compound mutations (11.5 months; 63.9%). Although sample sizes were small, notable activity was observed against specific exon 20 insertions at residues A763, M766, N771, and V769, and against osimertinib resistance mutations (G724S, L718X, C797S). Conclusion: Afatinib should be considered as a first-line treatment option for NSCLC patients with major uncommon, compound, 'other' (including E709X and L747X) and some specific exon 20 insertion mutations. Moderate activity was seen against osimertinib resistance
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.